

From: Michael Clarke </O=ONETEAM/OU=FIRST ADMINISTRATIVE GROUP/CN=RECIPIENTS/CN=MCLARKE>
To: Nancy Baran </ONETEAM/FIRST ADMINISTRATIVE GROUP/RECIPIENTS/NBARAN>
Sent: 9/26/2012 1:25:47 PM
Subject: RE: Jupiter, FL Distribution Center

Nancy,

The Walgreen email has been sent. Let's see what happens.

Michael

Michael R. Clarke
Actavis
973-889-6667
mailto:MCLARKE@actavis.com [MCLARKE@actavis.com]

From: Nancy Baran
Sent: Tuesday, September 25, 2012 5:37 PM
To: Michael Clarke
Subject: FW: Jupiter, FL Distribution Center

I am getting pressure to ship but do not feel that Walgreens has supplied us a sufficient amount of documentation. At bare minimum, the questions I outlined below are required. I had two additional questions that I eliminated from my first cut...because this was coming from me rather than a compliance role. If you are willing to send this out, guidance I received suggests we may want to ask the following:

What actions has Walgreens taken to ensure these products are not likely to be diverted?
How are you working with your wholesaler with respect to diversion matters?

I am off tomorrow but will keep an eye open for e-mails.
The recipients of this e-mail should be - (David Reiter and Bill Groth) with a copy to me.
Thanks,
Nancy

From: Reiter, David mailto:[mailto:david.reiter@walgreens.com]
[[mailto:david.reiter@walgreens.com]]
Sent: Monday, September 24, 2012 09:38 PM
To: Michael Dorsey
Cc: Groth, Bill <mailto:bill.groth@walgreens.com [bill.groth@walgreens.com]>

Nancy Baran
Director, Customer Service

_x0000_i1025
Actavis
60 Columbia Rd. Bldg B t +1 973-993-4510 or 888-925-2342 @ mailto:NBARAN@actavis.com
[NBARAN@actavis.com]
Morristown,NJ07960United States f +1-973-993-4300 w http://www.actavis.com/
[www.actavis.com]
Internal VoIP number t 1254510

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

From: Nancy Baran
Sent: Tuesday, September 25, 2012 2:48 PM



Confidential



Acquired_Actavis_00761668

P-02398 _ 00001

To: Michael Clarke
Cc: Michael Perfetto; Michael Dorsey; Rachelle Galant
Subject: FW: Jupiter, FL Distribution Center

*****I am requesting permission to e-mail the attached to Walgreens*****

David and Bill,

First of all, thank you for your time yesterday. I have read your e-mail below and have a few questions requiring further clarification.

Based on our conversation and as outlined in the attached letter, you have explained that Walgreens has effectively shifted 100% of its C2 products purchases for all stores in Florida and Georgia being serviced by Jupiter, Florida to Cardinal Health. The only exception is the stores located in Puerto Rico serviced by Jupiter, FL which will be supplied through Amerisource Bergen. The understanding is that any shift in purchases to Cardinal would be met with a reduction in equal or greater quantities ordered directly by Walgreens.

Please confirm how the usage as outlined below was calculated. Was this derived using historical averages and if so for what time period? Does this include any type of anticipated decrease in light of the DEA action? We would also need to get confirmation on your anticipated volumes shifting to Amerisource Bergen.

I will look forward to your reply.

Regards,

Nancy Baran

Nancy Baran
Director, Customer Service

_x0000_i1026
Actavis
60 Columbia Rd. Bldg B t +1 973-993-4510 or 888-925-2342 @ <mailto:NBARAN@actavis.com>
[NBARAN@actavis.com]
Morristown, NJ 07960 United States f +1-973-993-4300 w <http://www.actavis.com/>
[www.actavis.com]
Internal VoIP number t 1254510

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way. Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

From: Michael Dorsey
Sent: Tuesday, September 25, 2012 8:53 AM
To: Nancy Baran; Michael Perfetto; Diana Herbig; Rachelle Galant; Yvonne Hodges
Subject: Fw: Jupiter, FL Distribution Center

Nancy,

Please read the follow-up email from David from Walgreens and confirm that this matches up with our needs.

Thank you,

Mike Dorsey
Director, National Accounts
262.377.0874 (O)
262.421.4636 (F)
908.906.9838 (C)

From: Reiter, David [mailto:\[mailto:david.reiter@walgreens.com\]](mailto:[mailto:david.reiter@walgreens.com])

Confidential

Acquired_Actavis_00761669

P-02398_00002

[[mailto:david.reiter@walgreens.com]]

Sent: Monday, September 24, 2012 09:38 PM

To: Michael Dorsey

Cc: Groth, Bill <mailto:bill.groth@walgreens.com [bill.groth@walgreens.com]>

Subject: FW: Jupiter, FL Distribution Center

Hello Michael,

I wanted to follow the attached communication with some additional detail pertaining to your products. Below is the expected volume for our Florida and Georgia stores which are to be serviced by Cardinal through their Knoxville, Greensboro and Jackson DCs. Please let me know if you need anything further.

Vendor

DC

WIC

Description

Avg Weekly Volume (Florida and Georgia)

ACTAVIS TOTOWA C2

500014

496046

OXYCODONE/IBU 5/400MG TB(ACT)+100

2

ACTAVIS TOTOWA C2

500014

421149

OXYMORPHONE ER 15MG TAB (ACT)+100

4

ACTAVIS TOTOWA C2

500014

422502

METHYLPHEN 30MG ER CAP (ACT) +100

6

ACTAVIS TOTOWA C2

500014

422501

METHYLPHEN 40MG ER CAP (ACT) +100

7

ACTAVIS TOTOWA C2

Confidential

Acquired_Actavis_00761670

P-02398 _ 00003

500014

422503

METHYLPHEN 20MG ER CAP (ACT) +100

9

ACTAVIS TOTOWA C2

500014

422719

OXYCODONE HCL 15MG TAB (ACT)+ 100

1036

ACTAVIS TOTOWA C2

500014

427079

OXYCODONE HCL 30MG TAB (ACT)+ 100

1562

Thank you,
David W. Reiter
Manager
Pharmacy Inventory Supply and Strategy
Walgreen Co.
PH: 847-315-3156

This message is intended solely for the designated recipient(s). It may contain confidential or proprietary information and may be subject to attorney-client privilege or other confidentiality protections. If you are not a designated recipient you may not review, copy or distribute this message. If you receive this in error, please notify the sender by reply e-mail and delete this message. Thank you.

From: Feng, Michael
Sent: Wednesday, September 19, 2012 10:53 AM
Subject: Jupiter, FL Distribution Center

Please see attached letter regarding Walgreen Co. Jupiter, FL Distribution Center for schedule II pharmaceutical products.

Thank you,

Michael Feng
Purchasing Coordinator | Pharmacy
Walgreen Co.
Phone (847) 315-2781
Fax (847) 315-3675
mailto:Michael.Feng@walgreens.com [Michael.Feng@walgreens.com]

THE CONTENTS OF THIS EMAIL AND ITS ATTACHMENTS ARE WALGREEN CO. CONFIDENTIAL.
If you are not the intended recipient of this communication, please reply to the sender either by email or telephone (847-315-2781) that you have received this communication in error; then please delete this email without disclosing its contents to anyone. Thank you.

Confidential

Acquired_Actavis_00761671

P-02398 _ 00004